BioWorld

Nov. 18, 2010

Roche Steps Back from RNA Interference, Cuts 6% of Staff

As part of a cost-cutting corporate restructuring, Roche AG plans to discontinue its preclinical research in the area of RNA interference (RNAi) at sites in Kulmbach, Germany; Madison, Wisc.; and Nutley, N.J. (BioWorld Today) Read More

Avanir Raising $88M Post-Nuedexta Approval

From 'FAB' to Flush: Sutro Adding $36.5M in Series C

Investors Hammer Resverlogix Over Cholesterol Drug Data

Forma Will Get $20M from Eisai in Drug Discovery Deal

Clinic Roundup

Stock Movers

Other News To Note

Today's news in brief

BioWorld

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 14, 2026

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...

Selective CBL-B inhibitor with improved safety profile disclosed

BioWorld Science

CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...